comparemela.com

Latest Breaking News On - Xbiotech company profile - Page 8 : comparemela.com

Brickell Biotech (NASDAQ:BBI) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of Brickell Biotech (NASDAQ:BBI – Get Rating) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. Zacks Investment Research currently has $0.25 price target on the stock. According to Zacks, “Brickell Biotech, Inc. is a clinical-stage pharmaceutical company. It is focused on developing […]

Viva Biotech Holdings (OTCMKTS:VBIZF) Short Interest Down 62 1% in March

Viva Biotech Holdings (OTCMKTS:VBIZF – Get Rating) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 2,857,900 shares, a drop of 62.1% from the February 28th total of 7,541,000 shares. Based on an average daily volume of 700 shares, the days-to-cover ratio is currently 4,082.7 days. […]

Legend Biotech (NASDAQ:LEGN) Rating Lowered to Sell at Zacks Investment Research

Legend Biotech (NASDAQ:LEGN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and […]

Analysts Anticipate Brickell Biotech, Inc (NASDAQ:BBI) Will Post Earnings of -$0 08 Per Share

Brokerages forecast that Brickell Biotech, Inc. (NASDAQ:BBI – Get Rating) will post earnings per share of ($0.08) for the current quarter, according to Zacks. Three analysts have issued estimates for Brickell Biotech’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.12). Brickell Biotech posted earnings per share of ($0.15) during the same […]

Legend Biotech (NASDAQ:LEGN) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Legend Biotech (NASDAQ:LEGN – Get Rating) from a sell rating to a hold rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.